Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy.
Domingo
Pere
P
Sambeat
María A
MA
Pérez
Antonio
A
Ordoñez
Jordi
J
D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D001055:Apolipoproteins B / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged
D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D017320:HIV Protease Inhibitors; D008055:Lipids